Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 08/29 10:00:00 pm
2.9 USD   -0.68%
08/09 IMMUNOGEN : Announces Departure of Chief Development Officer
08/05 IMMUNOGEN, INC. : Announces Webcasts of Presentations at Upcoming In..
08/04 IMMUNOGEN : reports 4Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201420152016201720182019
Sales59,985,560,076,173,5111
Operating income (EBITDA)-66,9-54,4--102-116-136
Operating profit (EBIT)-71,5-59,9-124-121-130-116
Pre-Tax Profit (EBT)------
Net income-71,4-60,7-144-148-159-134
P/E ratio-14,3-20,3-1,87-1,77-1,75-2,18
EPS ( $ )-0,83-0,71-1,65-1,64-1,66-1,33
Dividend per Share ( $ )------
Yield------
Reference price ( $ )11.8514.383.082.92.92.9
Announcement Date08/01/2014
10:30am
07/31/2015
10:30am
08/04/2016
02:04pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201420152016201720182019
Debt---133107109
Finance142278245---
Operating income (EBITDA)-66,9-54,4--102-116-136
Leverage
(Debt/EBITDA)
----1,31x-0,92x-0,80x
Capital Expenditure8,187,4310,414,715,51,86
Book Value Per Share (BVPS)0,88 $0,41 $-0,93 $-2,11 $-1,81 $-1,81 $
Cash Flow per Share-0,63 $-0,64 $--1,07 $-0,83 $-
Announcement Date08/01/2014
10:30am
07/31/2015
10:30am
08/04/2016
02:04pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2017e 2018e
Capitalization 253 M$ -
Entreprise Value (EV) 386 M$ 361 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS)
Capitalization / Revenue 3,33x 3,45x
EV / Revenue 5,08x 4,91x
EV / EBITDA -3,79x -3,10x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -1,37x -1,60x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) -159% -177%
operating Leverage (Delta EBIT / Delta Sales) 0,09x -2,08x
Net Margin (Net Profit / Revenue) -194% -217%
ROA (Net Profit / Asset) -53,7% -60,8%
ROE (Net Profit / Equities) 126% 134%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / Sales   19,3% 21,0%
Cash Flow / Sales -123% -98,7%
Capital Intensity (Assets / Sales) 3,61x 3,57x
Financial Leverage (Net Debt / EBITDA) -1,31x -0,92x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend